FDA Announces Approval of Guidance on Biosimilar Meetings with FDA

Summary

The Food and Drug Administration (FDA) has received approval from the Office of Management and Budget (OMB) to collect information on formal meetings between the FDA and biosimilar biological product sponsors or applicants, as outlined in a new guidance document.